190 related articles for article (PubMed ID: 36506732)
21. Interaction of the chemotherapeutic agent oxaliplatin and the tyrosine kinase inhibitor dasatinib with the organic cation transporter 2.
Ahmed Eltayeb S; Dressler JM; Schlatt L; Pernecker M; Neugebauer U; Karst U; Ciarimboli G
Arch Toxicol; 2024 Jul; 98(7):2131-2142. PubMed ID: 38589558
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Huangqi Guizhi Wuwu Decoction for Oxaliplatin-Induced Peripheral Neurotoxicity: A Systematic Review and Meta-Analysis.
Yu J; Chen S; Wei G; Gu J; Huo J; Ding R; Li L
Altern Ther Health Med; 2024 Jan; 30(1):446-453. PubMed ID: 37820675
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of traditional plant-based medicines for preventing chronic oxaliplatin-induced peripheral neurotoxicity in patients with colorectal cancer: A systematic review and meta-analysis with core herb contribution.
Han J; Lai H; Li W; Liao H; Xiao C; Li X; You F; Guo J
J Ethnopharmacol; 2024 May; 326():117735. PubMed ID: 38211824
[TBL] [Abstract][Full Text] [Related]
24. The association between sociodemographic, clinical, and potentially preventive therapies with oxaliplatin-induced peripheral neuropathy in colorectal cancer patients.
Hines RB; Schoborg C; Sumner T; Zhu X; Elgin EA; Zhang S
Support Care Cancer; 2023 Jun; 31(7):386. PubMed ID: 37294347
[TBL] [Abstract][Full Text] [Related]
25. Duloxetine alleviates oxaliplatin-induced peripheral neuropathy by regulating p53-mediated apoptosis.
Wang M; Zhang L; Liu X; Qiu S; Xu R; Yang C; Lu Y; Zhang P; Yan M; Zhu J
Neuroreport; 2022 Jul; 33(10):437-444. PubMed ID: 35623085
[TBL] [Abstract][Full Text] [Related]
26. Platinum accumulation in oxaliplatin-induced peripheral neuropathy.
Wei G; Gu Z; Gu J; Yu J; Huang X; Qin F; Li L; Ding R; Huo J
J Peripher Nerv Syst; 2021 Mar; 26(1):35-42. PubMed ID: 33462873
[TBL] [Abstract][Full Text] [Related]
27. Study protocol: fish oil supplement in prevention of oxaliplatin-induced peripheral neuropathy in adjuvant colorectal cancer patients - a randomized controlled trial. (OxaNeuro).
Gehr NL; Karlsson P; Timm S; Christensen S; Hvid CA; Peric J; Hansen TF; Lauritzen L; Finnerup NB; Ventzel L
BMC Cancer; 2024 Feb; 24(1):168. PubMed ID: 38308227
[TBL] [Abstract][Full Text] [Related]
28. Study on efficacy and safety of Huangqi Guizhi Wuwu decoction treatment for oxaliplatin induced peripheral neurotoxicity: A protocol for a randomized, controlled, double-blind, multicenter trial.
Wei XM; Chen XF; Shu P; Jiang ZW; Wu XY; Zou X; Chen K; Shen B; Hu WW; Lu W; Shen WX; Li L; Wang JY; Zhao FJ; Yin QF; Cheng HB; Gu YH
Medicine (Baltimore); 2020 May; 99(22):e19923. PubMed ID: 32481364
[TBL] [Abstract][Full Text] [Related]
29. Duloxetine for the Prevention of Oxaliplatin Induced Peripheral Neuropathy: A Randomized, Placebo-Controlled, Double-blind Clinical Trial.
Aghili M; Darzikolaee NM; Babaei M; Ghalehtaki R; Farhan F; Razavi SZE; Rezaei S; Esmati E; Samiei F; Azadvari M; Farazmand B; Bayani R; Amiri A
J Gastrointest Cancer; 2023 Jun; 54(2):467-474. PubMed ID: 35426033
[TBL] [Abstract][Full Text] [Related]
30. Metabolomics analysis reveals characteristic metabolites in different levels of oxaliplatin-induced neurotoxicity.
Hua Y; Wang R; Liu Y; Liu Q; Qi X; Ding Y; Lv J
J Sep Sci; 2024 Jun; 47(11):e2400164. PubMed ID: 38819794
[TBL] [Abstract][Full Text] [Related]
31. Development of hepatic impairment aggravates chemotherapy-induced peripheral neuropathy following oxaliplatin treatment: Evidence from clinical and preclinical studies.
Miyamoto T; Domoto R; Sekiguchi F; Kamaguchi R; Nishimura R; Matsuno M; Tsubota M; Fujitani M; Hatanaka S; Koizumi Y; Wang D; Nishibori M; Kawabata A
J Pharmacol Sci; 2022 Mar; 148(3):315-325. PubMed ID: 35177211
[TBL] [Abstract][Full Text] [Related]
32. Oxaliplatin-induced peripheral neurotoxicity in colorectal cancer patients: mechanisms, pharmacokinetics and strategies.
Cheng F; Zhang R; Sun C; Ran Q; Zhang C; Shen C; Yao Z; Wang M; Song L; Peng C
Front Pharmacol; 2023; 14():1231401. PubMed ID: 37593174
[TBL] [Abstract][Full Text] [Related]
33. The Microglial Activation Inhibitor Minocycline, Used Alone and in Combination with Duloxetine, Attenuates Pain Caused by Oxaliplatin in Mice.
Sałat K; Furgała-Wojas A; Sałat R
Molecules; 2021 Jun; 26(12):. PubMed ID: 34208184
[TBL] [Abstract][Full Text] [Related]
34. Formononetin ameliorates oxaliplatin-induced peripheral neuropathy via the KEAP1-NRF2-GSTP1 axis.
Fang Y; Ye J; Zhao B; Sun J; Gu N; Chen X; Ren L; Chen J; Cai X; Zhang W; Yang Y; Cao P
Redox Biol; 2020 Sep; 36():101677. PubMed ID: 32823168
[TBL] [Abstract][Full Text] [Related]
35. Time-dependent discrepancies between physician-assessed and patient-reported oxaliplatin-induced peripheral neuropathy in patients with metastatic colorectal cancer who received mFOLFOX6 plus bevacizumab: a post hoc analysis (WJOG4407GSS2).
Miura Y; Ando M; Yamazaki K; Hironaka S; Boku N; Muro K; Hyodo I
Support Care Cancer; 2021 Jul; 29(7):3715-3723. PubMed ID: 33200233
[TBL] [Abstract][Full Text] [Related]
36. Paeoniflorin ameliorates oxaliplatin-induced peripheral neuropathy via inhibiting neuroinflammation through influence on gut microbiota.
Xu J; Lu L; Jiang S; Qin Z; Huang J; Huang M; Jin J
Eur J Pharmacol; 2024 May; 971():176516. PubMed ID: 38513881
[TBL] [Abstract][Full Text] [Related]
37. Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II/III colorectal cancer.
Wang DS; Wang ZQ; Chen G; Peng JW; Wang W; Deng YH; Wang FH; Zhang JW; Liang HL; Feng F; Xie CB; Ren C; Jin Y; Shi SM; Fan WH; Lu ZH; Ding PR; Wang F; Xu RH; Li YH
Cancer Med; 2020 Jan; 9(1):151-159. PubMed ID: 31724334
[TBL] [Abstract][Full Text] [Related]
38. An effective therapeutic approach for oxaliplatin-induced peripheral neuropathy using a combination therapy with goshajinkigan and bushi.
Mizuno K; Shibata K; Komatsu R; Omiya Y; Kase Y; Koizumi S
Cancer Biol Ther; 2016 Nov; 17(11):1206-1212. PubMed ID: 27416484
[TBL] [Abstract][Full Text] [Related]
39. Changes in chemotherapy-induced peripheral neuropathy, disturbance in activities of daily living, and depression following chemotherapy in patients with colorectal cancer: A prospective study.
Oh PJ; Lee JR; Kim SK; Kim JH
Eur J Oncol Nurs; 2020 Feb; 44():101676. PubMed ID: 31751847
[TBL] [Abstract][Full Text] [Related]
40. Prevention of oxaliplatin-induced peripheral neuropathy by a polyamine-reduced diet-NEUROXAPOL: protocol of a prospective, randomised, controlled, single-blind and monocentric trial.
Balayssac D; Ferrier J; Pereira B; Gillet B; Pétorin C; Vein J; Libert F; Eschalier A; Pezet D
BMJ Open; 2015 Apr; 5(4):e007479. PubMed ID: 25833669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
